Pharmaceutical Archives - Spark Newswire

2 minute read

Federal Trade Commission Targets ‘Junk Patent Listings’ For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca

May 1, 4:11 PM

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.

AMPH

2 minute read

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study

By Vandana Singh

April 16, 12:13 PM

Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.

ITCI

2 minute read

Bernie Sanders Blasts Big Pharma’s Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

By Nina Zdinjak

February 9, 10:10 AM

CEOs of Johnson & JohnsonÂ (NYSE:JNJ),Â Merck (NYSE:MRK) andÂ Bristol-Myers SquibbÂ (NYSE:BMY) defended the high prices of their drugs as they were…

BMY

1 minute read

Cautious Optimism For Bluebird Bio’s Sickle Cell Therapy: Analyst Sees Financial Challenges

By Vandana Singh

October 17, 2:40 PM

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.

BLUE

2 minute read

Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck

By AJ Fabino

June 29, 1:03 PM

Industry giant Morgan Stanley (NYSE:MS) is shaking up its model for income-focused investors, indicating a strategic move towards…

AMGN

Feed Tag: Pharmaceutical

Federal Trade Commission Targets ‘Junk Patent Listings’ For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study

Bernie Sanders Blasts Big Pharma’s Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Cautious Optimism For Bluebird Bio’s Sickle Cell Therapy: Analyst Sees Financial Challenges

Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck